NCT04932330 (ICU-AW) is a clinical trial in ICU Acquired Weakness, sponsored by Second Affiliated Hospital, School of Medicine, Zhejiang University.

Who is sponsoring NCT04932330?

NCT04932330 is sponsored by Second Affiliated Hospital, School of Medicine, Zhejiang University.

What condition does NCT04932330 study?

NCT04932330 studies ICU Acquired Weakness.

Is NCT04932330 still recruiting?

NCT04932330 is currently status unknown. Last updated 21 June 2021.

Last reviewed 2021-06-21 · How we verify

NCT04932330: ICU-AW

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Risk Factors of ICU-acquired Weakness

Status unknown Last updated 21 June 2021

What this trial tests

trial in ICU Acquired Weakness in 85 participants. Status unknown.

Timeline

1 March 2017

Primary endpoint
1 March 2020

1 June 2022

Quick facts

Lead sponsor	Second Affiliated Hospital, School of Medicine, Zhejiang University
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	85
Start date	1 March 2017
Primary completion	1 March 2020
Estimated completion	1 June 2022
Sites	1 location across China

Conditions studied

ICU Acquired Weakness — all drugs for ICU Acquired Weakness →

Sponsor

Second Affiliated Hospital, School of Medicine, Zhejiang University

Who can join

Adults 18 to 80, any sex, with ICU Acquired Weakness. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

We conducted a retrospective study of critical ill patients who used ECMO during their ICU stay. ICU-AW was diagnosed at the time when patients discharged and had a Medical Research Council (MRC) sum score \< 48 out of a maximal score of 60. We divided patients to ICU-acquired weakness group and no ICU-acquired weakness group and compared their clinical characteristics. Baseline characteristics and therapy details were collected from the case report forms and inspection reports. Univariable analysis and logistic regression analysis were used to analyze clinical characteristics of individuals and to find risk factors of ICU-AW.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for ICU Acquired Weakness

Currently open trials in the same condition.

NCT07167121 — Predictive Validity of the Chelsea Critical Care Physical Assessment Tool (CPAx) for Regaining Autonomy Three Months Aft · recruiting
NCT07162948 — ICU-Recover Box 2.0, Smart Technology for Home Monitoring of ICU Patients · NA · recruiting
NCT06592144 — TESTO-TRIAL: Use of Testosterone in Critically Ill Patients · Phase 4 · active not recruiting
NCT05919940 — Improved Muscle Metabolism by Combination of Muscle Activation and Protein Substitution ( IMEMPRO ) · NA · recruiting
NCT05865314 — Optimised Nutritional Therapy and Early Physiotherapy in Long Term ICU Patients (NutriPhyT Trial) · NA · recruiting

Other Second Affiliated Hospital, School of Medicine, Zhejiang University trials

Trials by the same sponsor.

NCT07445152 — Research on Construction and Verification of Multimodal Medical Imaging Large Model · not yet recruiting
NCT06775665 — A Real-World Study on Hypertrophic Cardiomyopathy in Chinese Population · not yet recruiting
NCT07533422 — Rescue Reatment of Helicobacter Pylori Based on Fecal Antimicrobial Resistance Gene Testing · NA · not yet recruiting
NCT07487285 — A Non-inferiority Study of Laser Combined With Ultrasonic Debridement Therapy (LCUDT) Versus Manual Combined With Ultras · NA · not yet recruiting
NCT07505186 — Camrelizumab, Chemotherapy and Ivarmacitinib in Patients With Resectable Esophageal Squamous Cell Carcinoma · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04932330 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Second Affiliated Hospital, School of Medicine, Zhejiang University
Last refreshed: 21 June 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04932330.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing